Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working …
CH Takimoto, SC Remick, S Sharma, S Mani… - Journal of clinical …, 2003 - ascopubs.org
Purpose: This study was undertaken to determine the toxicities, pharmacokinetics, and
maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop
formal guidelines for oxaliplatin dosing in this patient population. Patients and Methods:
Thirty-seven adult cancer patients with variable renal function received intravenous
oxaliplatin at 60 to 130 mg/m2 every 3 weeks. Patients were stratified by 24-hour creatinine
clearance (CrCL) into four cohorts: group A (controls, CrCL≥ 60 mL/min), group B (mild …
maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop
formal guidelines for oxaliplatin dosing in this patient population. Patients and Methods:
Thirty-seven adult cancer patients with variable renal function received intravenous
oxaliplatin at 60 to 130 mg/m2 every 3 weeks. Patients were stratified by 24-hour creatinine
clearance (CrCL) into four cohorts: group A (controls, CrCL≥ 60 mL/min), group B (mild …
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working …
TW Synold, CH Takimoto, JH Doroshow, D Gandara… - Clinical cancer …, 2007 - AACR
Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for
oxaliplatin dosing in this patient population. Experimental Design: Sixty adult cancer patients
with variable hepatic function received iv oxaliplatin ranging from 60 to 130 mg/m2 every 3
weeks. Patients were stratified by levels of total bilirubin, aspartate aminotransferase (AST),
and alkaline phosphatase (AP) into five cohorts based on the degree of hepatic dysfunction …
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for
oxaliplatin dosing in this patient population. Experimental Design: Sixty adult cancer patients
with variable hepatic function received iv oxaliplatin ranging from 60 to 130 mg/m2 every 3
weeks. Patients were stratified by levels of total bilirubin, aspartate aminotransferase (AST),
and alkaline phosphatase (AP) into five cohorts based on the degree of hepatic dysfunction …
以上显示的是最相近的搜索结果。 查看全部搜索结果